The peptide internet is mostly noise. We read the literature and the regulations, then write it for humans.
Evidence reviews, per-country regulatory clarity, and the changes that matter. Scannable, sourced, in plain English. Built for curious people, not just clinicians.
Why trust us
We don't sell peptides.
No shop, no commerce, no conflict.We don't take money for good reviews.
Methodology is disclosed; negative findings stand.We write for humans, not just clinicians.
Scannable, plain English, no jargon walls.Every claim has a source.
Linked to primary literature, not forums.Is it legal where you live?
All 7 countries →Almost every peptide guide online is written for the United States and quietly ignores that the EU and Nordics are stricter, and different country to country. We maintain a per-country tracker, sourced to the national medicines agencies and re-verified every quarter.
| Peptide | Denmark | Sweden | Norway | Germany | Netherlands | United Kingdom | United States |
|---|---|---|---|---|---|---|---|
| BPC-157 | Not authorised | Not authorised | Not authorised | Not authorised | Not authorised | Not authorised | Not approved |
| Semaglutide | Prescription | Prescription | Prescription | Prescription | Prescription | Prescription | Prescription |
| Tesamorelin | No EU authorisation | No EU authorisation | No EU authorisation | No EU authorisation | No EU authorisation | Unlicensed | Prescription |
| Ipamorelin | Not authorised | Not authorised | Not authorised | Not authorised | Not authorised | Not authorised | Not approved |
| Semax | Not authorised | Not authorised | Not authorised | Not authorised | Not authorised | Not authorised | Not approved |
| Tirzepatide | Prescription | Prescription | Prescription | Prescription | Prescription | Prescription | Prescription |
| Retatrutide | Investigational | Investigational | Investigational | Investigational | Investigational | Investigational | Investigational |
| TB-500 | Not authorised | Not authorised | Not authorised | Not authorised | Not authorised | Not authorised | Not approved |
| CJC-1295 | Not authorised | Not authorised | Not authorised | Not authorised | Not authorised | Not authorised | Not approved |
| PT-141 | No EU authorisation | No EU authorisation | No EU authorisation | No EU authorisation | No EU authorisation | Unlicensed | Prescription |
The peptide library
All entries →BPC-157
A 15-amino-acid synthetic peptide with extensive rodent literature on tendon, gut and brain repair, but essentially no controlled human evidence. Not an approved medicine anywhere, and WADA-prohibited under S0.
Semaglutide
The most-studied peptide we cover. Strong randomised-trial evidence for type-2 diabetes, weight loss, and (since SELECT in 2023) cardiovascular-event reduction in obesity without diabetes.
Tesamorelin
FDA-approved in the US (Egrifta) for HIV-associated lipodystrophy; no EU/EEA/UK marketing authorisation after Theratechnologies withdrew the European application in 2012. Off-label discussion is common but not trial-supported.
Ipamorelin
A selective pentapeptide growth-hormone secretagogue characterised in late-1990s pharmacokinetic work, with no published phase-2 or phase-3 efficacy trial. Not approved anywhere; WADA-prohibited under S2.
Semax
A Russian-developed synthetic heptapeptide nasal-spray nootropic, on the Russian List of Vital & Essential Drugs since 2011 for ischemic stroke recovery and cognitive indications. No marketing authorisation in the EU, EEA, UK or US, where it is sold through grey-market channels; the literature is large but heavily preclinical and in Russian-language journals.
Tirzepatide
A once-weekly dual GIP and GLP-1 receptor agonist sold as Mounjaro (type-2 diabetes) and Zepbound (chronic weight management and obstructive sleep apnea). Prescription-only across the EU, EEA, UK and US, with the largest single-trial weight-loss numbers in any approved obesity medicine: a mean 20.9% body-weight reduction at 72 weeks on 15 mg weekly in SURMOUNT-1 (Jastreboff et al., NEJM 2022).
Retatrutide
An investigational once-weekly subcutaneous triple receptor agonist from Eli Lilly. The Phase 2 obesity trial (Jastreboff et al., NEJM 2023) reported a mean weight reduction of 24.2% at 48 weeks on the 12 mg dose, the largest figure for a non-surgical obesity treatment to date. Phase 3 TRIUMPH-1 (obesity) and TRIUMPH-2 (type-2 diabetes) primary endpoints are scheduled to read out in 2026; the cardiovascular and kidney outcomes trial (TRIUMPH-Outcomes) runs to 2029. Not yet approved by the FDA, EMA, MHRA or any national agency we cover.
TB-500
A grey-market label commonly used for either full-length thymosin beta-4 (Tβ4, a 43-residue G-actin sequestering peptide) or its synthetic AC-LKKTETQ heptapeptide fragment. Preclinical literature on tissue repair, angiogenesis and cardiac protection is substantial; the only Western-standard human trial data is a small Phase 3 in neurotrophic keratopathy using the full-length Tβ4 ophthalmic solution RGN-259. Not authorised as a medicine anywhere we cover, and WADA-prohibited under S2 (peptide hormones, growth factors and related substances).
CJC-1295
A modified 30-amino-acid analogue of growth-hormone-releasing hormone, designed in the mid-2000s by ConjuChem to bind plasma albumin via a maleimidopropionyl linker and extend the half-life from minutes to roughly a week. Two small early-phase studies in healthy adults remain the strongest human data; the ConjuChem programme stalled after 2006 and no Phase 2 or Phase 3 efficacy trial has been completed. Not approved anywhere, WADA-prohibited under S2, and routinely conflated by online suppliers with the unrelated short-acting MOD-GRF(1-29).
PT-141
An MC3/MC4 receptor agonist, originally developed by Palatin Technologies in the 1990s as an intranasal erectile-dysfunction candidate before that programme was halted in 2007 over blood-pressure signals. Subsequently reformulated as a subcutaneous injection and FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women. No EU/EEA/UK marketing authorisation; widely used grey-market off-label for libido in both sexes.
The Saturday read
One honest peptide email a week. What the research says, what changed in the law, and what we'd ignore.